An experimental drug from the US-based Eli Lilly and Company discovered to protect Alzheimer's-inflicted mice from memory deterioration, despite a high-glycemic-index (GI) diet meant to boost blood sugar levels. The experimental drug mimics the hunger-signaling hormone ghrelin.
Upto 3% of the global population suffering from Ankylosing spondylitis and two other debilitating conditions. Ankylosing spondylitis, a painful form of arthritis is an incurable immune disease affecting the spine, joints and tendons, and can be difficult to diagnose.
A new research suggests that a simple blood or urine test could soon identify men with an elevated, genetically-inherited risk for the disease. The study is available online and will be published in an upcoming issue of the journal Cancer Discovery.
A team of researchers from University of Maryland found that Young adults who eat more fermented foods have fewer social anxiety symptoms. The study is published in the Psychiatry Research journal.
India and the European Union will soon begin research on health with focus on 'Diagnostics and interventions in chronic non-communicable diseases'. Main aim behind this collaboration is to support high quality research and development of tools and technologies for the diagnostics of chronic non-communicable diseases; research and innovation within interventions for chronic non-communicable diseases; and mechanisms in chronic non-communicable diseases. This will strengthen scientific, technology and business collaborations between Europe and India.
Savitribai Phule Pune University’s department of Interdisciplinary School of Health Sciences and Institute of Bioinformatics and Biotechnology have proved that Triphala, a widely used ayurvedic formulations, effective against a wide range of diseases like cardiovascular diseases, asthma, arthritis, diabetes and cancer. The team of scientists Uma Chandran, Neelay Mehendale, Girish Tillu and Prof. Bhushan Patwardhan used a technique known as poly-pharmacology. Triphala formulation as a whole contains 174 bioactives.
A study led by researchers at Case Western Reserve and UT Southwestern Medical Center showed An experimental drug help by regrow damaged liver, colon and bone marrow tissue in laboratory mice. Now scientist trying to work in humans. However, experts cautioned that their research is at a very early stage, and more work is needed before it can be tested in humans. This experimental drug is now known only as SW033291. It can shut down the activity of a gene product found in all humans, 15-hydroxyprostaglandin dehydrogenase (15-PGDH), that in turn allows room for more prostaglandin E2, which encourages many types of tissue stem cells to grow and promotes healing.
An antidepressant and a heart drug approved for use in humans may also help treat the deadly Ebola disease, a new study in mice suggests. Researchers screened about 2,600 compounds for their ability to hinder Ebola's activity, and identified 30 drugs that were effective against the virus in a lab dish. Two of the drugs — the antidepressant sertraline and a heart drug called bepridil - appeared particularly promising for their action against Ebola. The drugs appear to inhibit Ebola infection by preventing the genetic material of the virus from getting inside the host's cells.
Cinnamaldehyde, chemical constituent of cinnamon has distinctive flavor and smell. Associate Professor Georg Wondrak, and Professor Donna Zhang, at the University of Arizona recently completed a study in which they proved that adding cinnamaldehyde, the compound that gives cinnamon its distinctive flavor and smell, to the diet of mice protected the mice against colorectal cancer. In response to cinnamaldehyde, the mice's cells had acquired the ability to protect themselves against exposure to a carcinogen through detoxification and repair.
Results from an interim analysis of the Phase III RE-VERSE AD™ patient study demonstrate that 5 g of idarucizumab* immediately reversed the anticoagulant effect of dabigatran (Pradaxa®) in patients requiring urgent anticoagulant reversal. No safety concerns relating to idarucizumab* were identified. The results have been simultaneously published in the New England Journal of Medicine (NEJM) and presented today at the International Society of Thrombosis and Haemostasis 2015 Congress in Toronto, Canada.
[adsense:336x280:8701650588]
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
